


**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Beebe Medical Center c/o Radiology Dept.</p> <p>2. 424 Savannah Road Lewes, DE 19958</p>		<p>In accordance with letter dated December 08, 2021,</p>	<p>4. Expiration Date: June 30, 2024</p>
		<p>3. License No.: 07-17792-01 is amended in its entirety to read as follows:</p>	<p>5. Docket No.: 030-13331 Reference No.:</p>
<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 1000 millicuries total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.</p>



**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 07-17792-01

Docket or Reference No.:  
030-13331

Amendment No. 56

**CONDITIONS**

10. A. Licensed material may be used or stored at the licensee's facilities located at 424 Savannah Road, Lewes, Delaware.
- B. Licensed material listed in Subitem No. 6.B. may be used or stored at the licensee's facilities located at Beebe Health Campus, Bookhammer Outpatient Center, 18941 John J. Williams Highway (Route 24), Rehoboth Beach, Delaware.
- C. Licensed material listed in Subitem No. 6.B. may be used or stored at the licensee's facilities located at 19161 Healthy Way, Rehoboth Beach, Delaware.
11. The Radiation Safety Officer for this license is Lisa Marie Genovese, DMP.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized Users</u>        | <u>Material and Use</u>  |
|--------------------------------|--|
| Georges Abdul-Karim Dahr, M.D. | 10 CFR 35.200  |
| Ramon Alberto Rosa, M.D.       | 10 CFR 35.200  |
| Ellen Bahtiaran, M.D.          | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300  |
| Steven R. Chmielewski, M.D.    | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300  |
| Brian Costleigh, M.D.          | 10 CFR 35.300  |
| Andrew Dahlke, M.D.            | 10 CFR 35.100, 10 CFR 35.200   |
| Barry S. Denenberg, M. D.      | 10 CFR 35.200  |
| Frances Esposito, M.D.         | 10 CFR 35.100, 10 CFR 35.200, 10 CFR 35.300  |
| Dennis Michael Flamini, D.O.   | 10 CFR 35.100, 10 CFR 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131 |

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 07-17792-01

Docket or Reference No.:  
030-13331

Amendment No. 56

Authorized Users

Mouhanad K. Freih, M. D.

Kimberly Gardner, M. D.

Jeffrey McCann, M.D.

Rajinder Prasad, M.D.

Michael Ramjattansingh, M.D.

Material and Use

10 CFR 35.100,10 CFR 35.200

10 CFR 35.100,10 CFR 35.200; 10 CFR 35.300, limited to the oral administration of sodium iodide I-131

10 CFR 35.100,10 CFR 35.200

10 CFR 35.200

10 CFR 35.100,10 CFR 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
14. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Letter dated January 20, 2011, except shielding assessment [ML110200525]
- B. Letter dated February 7, 2011 [ML110390314]
- C. Facility diagrams received March 19, 2012 [ML120790362]
- D. Application dated December 18, 2013 [ML14014A072]
- E. Letter dated May 29, 2014 [ML14163A664]
- F. Letter dated July 21, 2017 [ML17236A325]
- G. Letter dated February 14, 2018 [ML18058A586]

Continued

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License No.: 07-17792-01

Docket or Reference No.:  
030-13331

Amendment No. 56

- H. Letter dated January 13, 2021 [ML21034A146]
- I. Letter dated January 20, 2021 [ML21049A249]
- J. Letter dated February 5, 2021 [ML21049A254]
- K. Letter and attachments dated February 17, 2022 [ML22049A026]



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: February 18, 2022

By: \_\_\_\_\_

Robin Elliott  
Region 1